Kappa Opioid Receptor Ligands and Pharmacology: Diphenethylamines, a Class of Structurally Distinct, Selective Kappa Opioid Ligands | SpringerLink
Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics
Cara Therapeutics - Invest In Weed
Cara Therapeutics: Scratching An Itch Left Unscratched (NASDAQ:CARA) | Seeking Alpha
Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression<b>:</b> A randomized,
Frontiers | Advances in Achieving Opioid Analgesia Without Side Effects
Peripheral kappa opioid receptor activation drives cold hypersensitivity in mice | bioRxiv
Experimental Kappa Opioid Appears Safe and Effective
PDF) Purification of a kappa-opioid receptor subtype from frog brain | Mária Szücs, Anna Borsodi, and Kálmán Medzihradszky - Academia.edu
Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics
Cara Therapeutics: Scratching At Multiple Indications In 2020 (NASDAQ:CARA) | Seeking Alpha
Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications - ScienceDirect
1Washington University, St. Louis, MO, USA; 2Trevi Therapeutics, New Haven, CT, USA; 3University of Miami, Miami, FL, USA Introd
Cara Therapeutics: Developing Novel Peripheral Kappa Opioid Product Candidates
κ-opioid receptor - Wikipedia
Peptide Kappa Opioid Receptor Ligands and Their Potential for Drug Development | SpringerLink
PDF) Evaluation of the abuse potential of difelikefalin, a selective kappa‐ opioid receptor agonist, in recreational polydrug users
Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Mark
A New Path to Pain Relief: Time for a Change with a Peripherally Acting Kappa Opioid Receptor Agonist (KORA)Friday, March 17, 201712:30 PM – 1:30 PMGrand Caribbean Ballroom 7Loews Sapphire Falls ResortOrlando, Florida Survey
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Difelikefalin: First Approval
EX-99.2
A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect
Articles with Cara Therapeutics, Inc. | page 5
